By contrast, the TAK-1 inhibitor 5Z-7-oxozeaenol significantly reduced pulmonary vascular remodeling and limited lung inflammation, induced a modest improvement in vascular remodeling and attenuated the metabolic reprogramming in RV and PASMCs in the rat SuHyp model of PAH. This evidence concerns the gene MAP3K7 and pulmonary arterial hypertension.